Jane Street Group LLC Purchases New Holdings in Atyr PHARMA INC (NASDAQ:ATYR)

Jane Street Group LLC purchased a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 199,006 shares of the company's stock, valued at approximately $720,000. Jane Street Group LLC owned 0.24% of Atyr PHARMA as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ATYR. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA during the fourth quarter worth $36,000. Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. purchased a new position in Atyr PHARMA during the 4th quarter valued at $39,000. JPMorgan Chase & Co. grew its holdings in shares of Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after purchasing an additional 10,754 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $40,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ATYR shares. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Monday, May 19th. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Stock Performance

Shares of NASDAQ:ATYR remained flat at $4.26 on Friday. The stock had a trading volume of 468,851 shares, compared to its average volume of 944,026. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a market capitalization of $379.16 million, a P/E ratio of -4.53 and a beta of 0.79. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The business has a 50-day moving average of $3.26 and a 200 day moving average of $3.44.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.